1. Hrubesz G, Dwyer K, McIsaac D, Sood M, Clark E, Douketis J, Carrier M, Shaw JR. Perioperative Management of Apixaban in Patients with Advanced CKD Undergoing a Planned Invasive Procedure. Blood Adv. 2024 Feb 13;8(3):732-735.

2.Shaw JR, James T, Douxfils J, Dargaud Y, Levy JH, Brinkman HJM, Shorr R, Siegal D, Castellucci LA, Gross P, Khalife R, Sperling C, Page D, Fergusson D, Carrier M. (2023) Thrombin generation, bleeding and hemostasis in humans: Protocol for a scoping review of the literature. PLoS One. 2023 Nov 1;18(11)

3. Shaw JR, Li N, Abdulrehman J, Stella SF, St John M, Nixon J, Spyropoulos AC, Schulman S, Wang TF, Carrier M, Douketis JD. (2023) Periprocedural Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Active Cancer. J Thromb Haemost. 2023 Nov 8:S1538-7836(23)00830-9. doi: 10.1016/j.jtha.2023.10.028. Epub ahead of print. PMID: 37949316

4. Shaw JR, Unachukwu U, Cyr J, Siegal DM, Castellucci LA, Dreden PV, Dowlatshahi D, Buyukdere H, Ramsay T, Carrier M. (2023) Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale. TH Open. 2023 Jul 25;7(3):e229-e240.

5.Lun R., Shaw JR., Roy DC., Siegal D., Ramsay T., Chen Y., Dowlatshahi D. (2023). Effect modification of age and hypertension on cancer and prevalence of self-reported stroke – A cross-sectional study. Cancer Med; 2023 Apr 21 

6.Shaw JR., Castellucci LA., Siegal D., Carrier M. DOAC-associated bleeding, hemostatic strategies and thrombin generation assays - a review of the literature. J Thromb Haemost. 2023 Mar;21(3):433-452

7. Aziz J., Wang TF., Siegal D., Douketis J., Le Gal G., Carrier M., Shaw JR. Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer. J Thromb Haemost. 2023 Apr;21(4):933-943.

8. Shaw JR., Li N., Nixon J., Moffat KA., Spyropoulos AC., Schulman S., Douketis JD. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure. J Thromb Haemost. 2022 Dec;20(12):2953-2963

9.Shaw JR., Kumar V., Mallick R., Carrier M., Ilich A., Key N., Wells P. (2020) Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thromb Res; 196: 437-443

10.Shaw JR., Li N., Vanassche T., Coppens M., Spyropoulos A.C., Syed S., Radwi M., Duncan J., Schulman S., Douketis J. (2020) Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Advances; 4(15): 3520-3527

11. Shaw JR., Kaplovitch E., Douketis J. (2020) Periprocedural management of oral anticoagulation. Med Clin North Am; 104(4): 709-726

12. Shaw JR., Siegal D.M. (2020). Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact? Res Pract Thromb Haemost; 4(5): 677-679

13. Shaw JR., Douketis J., Le Gal G., Carrier M (2019). Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost; 17(7): 1171-1178

14. Shaw JR., Siegal D.M. (2018). Pharmacological reversal of the direct oral anticoagulants – A comprehensive review of the literature. Res Pract Thromb Haemost; 2:251-265